期刊文献+

TRFIA技术定量检测HBV-M两对半的临床应用分析 被引量:1

Application analysis of quantitative detection of the second liver two half-and-half of HBV-M with TRFIA Tachnique
下载PDF
导出
摘要 目的探讨时间分辨荧光免疫分析(TRFIA)技术在定量检测乙型肝炎(乙肝)病毒(HBV)感染者的血清学标志物(HBV-M)乙肝两对半的临床应用价值。方法采用WallacVICTOR2-1420型多标记分析仪对539份乙肝患者血清标本进行乙肝两对半定量测定。为方便表述,以数字序号1、2、3、4、5分别代表乙肝两对半中的HBsAg、HBsAb、HBeAg、HBeAb、HBcAb,并以检出阳性项目的序号为该模式的代码。结果本文病例乙肝两对半的标记模式根据临床应用的实际可分为大三阳(135)组,小三阳(145)组,其他阳性的少见模式组和恢复期组,全部病例共检出18种模式。其中"135"组和"145"组占全部病例的48.40%;恢复期组以"25"和"245"模式为主,占全部病例的29.9%。结论血清HBV标志物乙肝两对半的表现模式较为复杂,除了检验误差外,产生少见模式的检出主要是TRFIA这种灵敏度高,特异性强和重复性好的技术,可以检出血清低水平阳性的HBsAg、HbsAb,有助于乙肝患者疾病的早期诊断、避免漏诊、临床合理用药、动态综合评价疗效,提供可靠的依据,值得在临床推广。 Objective To explore the clinical value of quantitative detection of the second liver two half-and-half of HBV-M with TRFIA Tachnique. Methods Quantitative detection of the second liver two half-and-half of 539 Hepatitis B Virus Inefction serum markers with Wallac VICTOR2-1420 markers analyzer.For fornulation clearly, adopt number of one,two,three,four,five to stand for HBsAg,HBsAb,HBeAg,HBeAb,HbcAb in second liver two half-and-half and the number of positive item is the code of model. Results Mark model of second liver two half-and-half is divided into the group of HbsAg+/eAg+/cAb+(135),the group of HbsAg+/eAb+/cAb+(145),the group of seldom seen model and the group of recovery. The Eighteen models were test in all cases. The group of (135) and "145" is 48.40 percent; the group of recovery with the model of "25"and "245"is 29.9 percent. Conclusion The model of the second liver two half-and-half of HBV-M is complicated.Expect for testing errors, the reason of the seldom seen model was tested is the TRFIA is highly sensitive, strong specific and good repeatability. It can test serum low level positive HBsAg,HbsAb. It is helpful to early diagnosis of second liver patients and to avoid misdiagnosis. It provides a reliable method for rational medication in clinical and synthtic evaluation on clinical curative effect. It is worth to be beintroduced in the clinical.
出处 《中国现代药物应用》 2011年第20期3-5,共3页 Chinese Journal of Modern Drug Application
关键词 时间分辨荧光免疫分析 乙肝病毒 血清标志物 定量 Time-resolved Huorescence Immunoassay Hepatitis B Virus Serum markers Quantitative Analysis
  • 相关文献

参考文献6

二级参考文献44

  • 1Zhang XX, Liu CM, Gong QM, et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J Gastroenterolo Hepatolo, 2003, 1353-1357.
  • 2Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut, 2000, 46: 562-568.
  • 3Maria Buti, Rafael Esteban. Entecavir, FTC, L-RMAU, LdT and others. J Hepatol, 2003, 39: S139-S142.
  • 4Kirishima T, Okanoue T, Daimon Y, et al. Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol, 2002, 37: 259-265
  • 5Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: an update. J Gastroenterol Hepatol, 2003, 18: 239-245.
  • 6The EASL Jury. EASL international consensus conference on hepatitis B. J Hepatol, 2003, 38: 533-540.
  • 7Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology, 2001, 34: 1225-1241.
  • 8Li LL, Chun TW, Yin ML, et al. Prophylactic lamivudine prevents hepatitis B reactivation and mortality in patients receiving immunosuppression and chemotherapy. Hepatology, 2000, 32(Pt 2): 1183.
  • 9Liaw YF, Sung JJY, Chow WC, et al. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blined placebo-controlled clinical trial. Hepatology, 2003, 38(Suppl)1: 262A.
  • 10Fontana RJ. Mangement of patients with decompensated HBV cirrhosis. Seminars in liver disease. 2003 23: 89-100.

共引文献454

同被引文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部